Hostname: page-component-745bb68f8f-f46jp Total loading time: 0 Render date: 2025-01-11T03:00:01.019Z Has data issue: false hasContentIssue false
  • English
  • Français

Catatonia and the Neuroleptic Malignant Syndrome – a Single Entity?

Published online by Cambridge University Press:  02 January 2018

D. A. C. White
D. A. C. White*
Affiliation:
Department of Psychiatry, University of Cape Town and Groote Schuur Hospital, Observatory 7925, South Africa
Get access Rights & Permissions [Opens in a new window]

Abstract

Separate episodes of both catatonia and the so-called ‘neuroleptic malignant syndrome’ (NMS) occurred within the same patient. The only evidence for NMS in this case was prior administration of a neuroleptic and the presence of generalised muscular rigidity. It is suggested that it is misleading to view these conditions as separate diagnostic entities and that NMS is probably more correctly incorporated into the catatonic disorders.

Type
Brief Reports
Information
The British Journal of Psychiatry , Volume 161 , Issue 4 , October 1992 , pp. 558 - 560
Copyright
Copyright © 1992 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Craddock, B., Craddock, N. & Milner, G. (1991) CPK in NMS. British Journal of Psychiatry, 158, 130.CrossRefGoogle ScholarPubMed
Harsch, H. H. (1987) Neuroleptic malignant syndrome: physiological and laboratory findings in a series of nine cases. Journal of Clinical Psychiatry, 48, 328–333.Google Scholar
Itoh, H., Ohtsuka, N., Ogita, K., et al (1977) Malignant neuroleptic syndrome: its present status in Japan and clinical problems. Folia Psychiatrica et Neurologica Japanica, 31, 565–576.Google ScholarPubMed
Keck, P. E., Harrison, G., Pope, H. G., et al (1989) Risk factors for neuroleptic malignant syndrome. Archives of General Psychiatry, 46, 914–918.CrossRefGoogle ScholarPubMed
Kellam, A. M. P. (1987) The neuroleptic malignant syndrome, so-called. A survey of the world literature. British Journal of Psychiatry, 150, 752–759.CrossRefGoogle ScholarPubMed
Mann, S. C., Caroff, S. N., Bleier, H. R., et al (1986) Lethal catatonia. American Journal of Psychiatry, 143, 1374–1381.Google ScholarPubMed
Menza, M. & Harris, D. (1989) Benzodiazepines and catatonia. An overview. Biological Psychiatry, 26, 842–846.CrossRefGoogle ScholarPubMed
Otani, K., Horiuchi, M., Kondo, T., et al (1991) Is the predisposition to neuroleptic malignant syndrome genetically transmitted? British Journal of Psychiatry, 158, 850–853.CrossRefGoogle ScholarPubMed
Rosebush, P. & Stewart, T. (1989) A prospective analysis of 24 episodes of neuroleptic malignant syndrome. American Journal of Psychiatry, 146, 717–725.Google ScholarPubMed
Rosebush, P. & Mazurek, M. (1991) Serum iron and the neuroleptic malignant syndrome. Lancet, 338, 149–151.CrossRefGoogle ScholarPubMed
White, D. & Robins, A. H. (1991) Catatonia: harbinger of the neuroleptic malignant syndrome. British Journal of Psychiatry, 158, 419–421.CrossRefGoogle ScholarPubMed
White, D. & Robins, A. H. (1991) Letter. British Journal of Psychiatry, 158, 858–859.CrossRefGoogle Scholar
Submit a response

eLetters

No eLetters have been published for this article.